I am a hematologist who specializes in treating people with multiple myeloma and other plasma cell disorders. This includes monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma, which are both conditions that can turn into multiple myeloma.

I primarily see patients with multiple myeloma. I also see people in whom the myeloma has returned, as well as those for whom the cancer does not respond to standard treatments. For these patients, we consider salvage therapies and novel immunotherapies, a type of cancer treatment that uses the patient’s immune system to fight cancer.

At Memorial Sloan Kettering Cancer Center (MSK), our myeloma team provides highly specialized and innovative care for patients with multiple myeloma. Patients have access to the latest treatments as well as a vast portfolio of novel therapies.